Retinopathy

Virginia Milk Bank Seeks Donors for Hospitalized Babies

Retrieved on: 
Wednesday, March 20, 2024
Breast milk, Jaundice, Retinopathy, Nutrient, Lactation, Disease, Memory, Short bowel syndrome, CHKD, Risk, Necrotizing enterocolitis, Hospital, Milk, American Academy, Infant, Death, NICU, Life, Protein, Kidney disease, Intraparenchymal hemorrhage, Woman, Holiday, Antibody, Oxygen, Premature, Paratriathlon, Charli, ROP, Pediatrics (journal), Pediatrics, Dairy

Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.

Key Points: 
  • Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.
  • After two weeks of consistently pumping with scant results, Moultrie was grateful to learn that Charli could receive safe, pasteurized human milk through the hospital's donor milk bank.
  • The milk bank also has a legacy program for women who have lost a baby but want to donate their milk to help other infants.
  • “But there are times around the holidays and during the summer when we only have enough milk for hospitalized babies.”
    This means the milk bank is not always able to provide milk to babies who have been discharged from the hospital with a doctor’s prescription for pasteurized donor human milk.

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

Retrieved on: 
Tuesday, March 5, 2024
Health, Diabetes, Clinical Trials, Research, Science, Optical, Biotechnology, Therapy, ARVO, Growth, Eye, Diabetic retinopathy, Safety, Alternative splicing, VEGF, Patient, Retinopathy, Phase, Trial of the century

These data demonstrate the safety and tolerability of EXN407, as well as clear indications of biological activity, positioning it well for further development as the first topical treatment for retinal vascular diseases such as diabetic retinopathy and diabetic macular oedema.

Key Points: 
  • These data demonstrate the safety and tolerability of EXN407, as well as clear indications of biological activity, positioning it well for further development as the first topical treatment for retinal vascular diseases such as diabetic retinopathy and diabetic macular oedema.
  • Exonate is now planning to progress EXN407 to the CLEAR-DM (Clinical Evaluation of a New Eyedrop for Alleviating Retinopathy in Diabetic Macular Oedema) Phase IIb clinical trial.
  • The mild NPDR/DME (NCT04565756) clinical study assessed the safety, tolerability and signals of biological response to EXN407 monotherapy in a double-masked, placebo-controlled Phase Ib/IIa dose-ranging clinical trial in treatment-naïve patients with mild/moderate non-proliferative diabetic retinopathy (NPDR) and mild diabetic macular oedema.
  • “The results suggest that topical ocular EXN407 may provide clinical benefit and substantially reduce the injection burden for patients with diabetic eye disease.

Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of Inaugural ROP Awareness Week, Feb. 26 - March 3, 2024

Retrieved on: 
Wednesday, February 21, 2024
Education, Medical director, Medical statistics, Parent, Infant, Pregnancy, University, Organization, Retinopathy, Diagnosis, Gestational age, Head, Social media, Section, Mental health, MBA, Associate professor, MSC, Initiative, Doctor of Psychology, Distribution, Partnership, FACS, National Eye Institute, Ear, University of Illinois Urbana-Champaign, Paratriathlon, ROP, Visual impairment, Safety, Division, MD, Visual Science, Diversity, Patient, Nursing

CHICAGO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has launched the new "Retinopathy of Prematurity Education and Support Program," as part of its first ROP Awareness Week, declared Feb. 26 – March 3, 2024. The group is offering a variety of free educational resources to the public and professionals, including fact sheets, social media graphics in English and Spanish, dedicated online resources, and a new video series.

Key Points: 
  • "Diagnosing and treating ROP early is essential for preventing or lessening ROP-associated vision loss," said Jeff Todd, president and CEO of Prevent Blindness.
  • To help address the need for ROP awareness and education, Prevent Blindness convened leading organizations in the parent support, education, and advocacy arenas to partner on creating the ROP Education and Support Program.
  • The ROP Education and Support Program and ROP Awareness Week is supported by funding from Regeneron .
  • In the Prevent Blindness Focus on Eye Health Expert Series, " Retinopathy of Prematurity ," Jeff Todd, president and CEO of Prevent Blindness, interviews R.V.

Richard F. Spaide, MD of the Vitreous Retina Macula Consultants of New York Awarded the Arnall Patz Medal by the Macula Society

Retrieved on: 
Tuesday, February 20, 2024
Research, MD, Consultant, Premature, Retinopathy, Annual general meeting, Arnall Patz, Book

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Vitreous Retina Macula Consultants of New York ( VRMNY ), the largest retina vitreous center in the New York Metropolitan area, has announced that its esteemed ophthalmologist Richard F. Spaide, MD, was awarded the Arnall Patz Medal at The Macula Society 's 47th Annual Meeting on February 9th, 2024.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Vitreous Retina Macula Consultants of New York ( VRMNY ), the largest retina vitreous center in the New York Metropolitan area, has announced that its esteemed ophthalmologist Richard F. Spaide, MD, was awarded the Arnall Patz Medal at The Macula Society 's 47th Annual Meeting on February 9th, 2024.
  • Dr. Spaide was selected as the honoree of the Arnall Patz Medal by the awards committee of The Macula Society.
  • The Macula Society is the preeminent organization for specialists in the field of macula and retinal diseases.
  • The Arnall Patz Medal is awarded to those who have made outstanding contributions to the understanding of retinal vascular diseases in honor of ophthalmologist Arnall Patz, who is known for his landmark work on retinopathy of prematurity.

Stiffening of retinal blood vessels threatens vision in diabetes

Retrieved on: 
Tuesday, November 21, 2023
American Diabetes Association, Associate, Vision, UCLA, Capillary, Risk, DR, Research, Physics, Diabetic retinopathy, Paratriathlon, Blood, UC, Mouse, Health, MD, Doheny Eye Institute, Retinopathy, Patient, Retina, University of California, Irvine, Pharmaceutical industry

With the global surge in diabetes cases, the risk of diabetic retinopathy (DR), a vision-threatening complication affecting nearly 40% of all individuals with diabetes, has also escalated significantly.

Key Points: 
  • With the global surge in diabetes cases, the risk of diabetic retinopathy (DR), a vision-threatening complication affecting nearly 40% of all individuals with diabetes, has also escalated significantly.
  • Late-stage DR, characterized by multiplication and leakiness of smaller blood vessels (capillaries) in the retina, often leads to vision loss.
  • That diabetes causes stiffening of large blood vessels is already known.
  • "If larger blood vessels can become stiffer in diabetes, perhaps so could the smaller retinal capillaries", reckoned Kaustabh Ghosh, senior author of the study and Associate Professor of Ophthalmology at UCLA and Doheny Eye Institute.

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

Retrieved on: 
Monday, December 18, 2023
Health, FDA, Parenting, Medical Devices, Baby, Maternity, Hospitals, Health Technology, Consumer, PR, Multimedia, Stork, Loma Linda University, Research, NICU, Parent, Hospital, Incidence, Pulse, Pediatrics, Hospital medicine, Motion, Skin temperature, Temperature, MASI, Retinopathy, QHD, Oxygen saturation (medicine), Extremis, Perfusion, ARMS, Patient, Safety, Vital signs, Skin, Child, Pharmaceutical industry

Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.

Key Points: 
  • Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.
  • Leveraging the same Masimo sensor technology that monitors more than 10 million babies in hospitals every year, Stork provides continuous, accurate monitoring of a baby’s health.
  • In addition, Stork alerts parents if their baby turns over and is sleeping face down, which can be dangerous for babies.
  • For prescription use, Masimo Stork is 510(k) cleared for the following intended use: Masimo Stork is a wearable device intended for the monitoring of multiple physiological parameters.

Prolacta's Human Milk-Based Nutrition Has Touched the Lives of 100,000 Premature and Critically Ill Infants Globally

Retrieved on: 
Friday, November 17, 2023
Hospice and palliative medicine, Necrotizing enterocolitis, Disease, Premature, NICU, Pediatrics, Medical Center, BPD, Prenatal care, Neonatology, Mortality, ROP, Monica E. Peek, Place of birth, Retinopathy, Division, Health, Bronchopulmonary dysplasia, Exclusive, MD, Mother, Death, Extrapyramidal system, Hospital, Singing, NEC, Dietary supplement, Nursing, Birth control

DUARTE, Calif., Nov. 17, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, proudly commemorates Prematurity Awareness Month 2023 by announcing a significant milestone: more than 100,000 preterm and critically ill infants' lives have been touched by Prolacta's Exclusive Human Milk Diet (EHMD) in hospitals worldwide.1

Key Points: 
  • "We're proud that for more than two decades, Prolacta's 100% human milk-based nutritional products have supported hospitals on the forefront of progressive care to help so many fragile infants in need."
  • The Peeks advocated for Leah Michelle to be on an EHMD and asked the hospital to fortify Brandi's breast milk with a Prolacta fortifier.
  • All types of hospitals have seen the benefits of an EHMD to treat the critically ill, premature infants in their care, including those supporting underserved populations.
  • One example is Los Angeles General Medical Center (formerly LAC+USC Medical Center), among the largest public hospitals in the U.S.

Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO

Retrieved on: 
Wednesday, November 8, 2023
FDA, IND, AAV, Trans-splicing, Food, Therapy, ATP, RNA, ABCA4, Retinopathy, Ascidian mitochondrial code, Exon, Regulation of tobacco by the U.S. Food and Drug Administration, Society, Cell, Stargardt disease, Risk, Gene, Animal, Drug discovery, DNA, Pharmaceutical industry, Vaccine, Stargardt, Ascidiacea

BOSTON, Nov. 8, 2023 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, today announced $40 million in Series A extension funding committed by Apple Tree Partners (ATP). The funds will be used to advance Ascidian's lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the company's pipeline. The company also announced that its founding CEO Michael Ehlers, M.D., Ph.D., will return as interim President and Chief Executive Officer, effective immediately. Dr. Ehlers, who also chairs Ascidian's Board of Directors and serves as Chief Scientific Officer at ATP as well as a venture partner at the firm, succeeds Romesh Subramanian, Ph.D., who is departing Ascidian.

Key Points: 
  • The company also announced that its founding CEO Michael Ehlers, M.D., Ph.D., will return as interim President and Chief Executive Officer, effective immediately.
  • Dr. Ehlers, who also chairs Ascidian's Board of Directors and serves as Chief Scientific Officer at ATP as well as a venture partner at the firm, succeeds Romesh Subramanian, Ph.D., who is departing Ascidian.
  • Today's announced financing follows ATP's initial $50 million Series A investment in Ascidian announced in October 2022.
  • Beyond its lead program, Ascidian is advancing programs with first-in-class potential in neurological and neuromuscular disorders.

American Academy of Ophthalmology and FundamentalVR Collaborate on Virtual Reality Initiative to Improve Ophthalmic Training Around the World

Retrieved on: 
Friday, November 3, 2023
Orbis, VR, Orbis International, MD, AAO, Organization, American Academy of Ophthalmology, Environment, Curriculum, American Academy, Virtual reality, Retinopathy, Video, Paratriathlon, Premature, ROP, Patient, Nursing, Ophthalmology

SAN FRANCISCO, Nov. 3, 2023 /PRNewswire/ -- The American Academy of Ophthalmology has teamed up with FundamentalVR, a leader in virtual reality (VR) medical training, for their Knights Templar Eye Foundation (KTEF) Pediatric Ophthalmology VR Simulation Program. This collaboration, made possible by a generous $5 million donation from the Knights Templar Eye Foundation, marks a significant step towards revolutionizing pediatric ophthalmic training by harnessing the power of VR technology through a free and open simulation program for ophthalmologists and ophthalmology trainees worldwide.

Key Points: 
  • Shaping the Future of Ophthalmology: The Academy and FundamentalVR Spearhead a Groundbreaking VR-Powered Clinical Education Initiative to Transform Ophthalmic Training
    SAN FRANCISCO, Nov. 3, 2023 /PRNewswire/ -- The American Academy of Ophthalmology has teamed up with FundamentalVR , a leader in virtual reality (VR) medical training, for their Knights Templar Eye Foundation (KTEF) Pediatric Ophthalmology VR Simulation Program.
  • In the past year, the Academy and FundamentalVR have made significant strides in the development of this pioneering educational platform.
  • "The potential to improve training programs is huge," said Faruk H. Orge, MD, executive editor of the KTEF Pediatric Ophthalmology Education Center.
  • "Just as virtual reality has greatly enhanced the experience of video games, so can being immersed in a virtual surgical training environment.

Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program

Retrieved on: 
Thursday, October 26, 2023
General Health, Diabetes, Health, Pharmaceutical, Health Technology, Adjustment, Eastern Time Zone, International, Dexcom, Share repurchase, GAAP, ONE, EASD, CGM, Toys "R" Us Canada, ID, Risk, Retinopathy, Webcast, Annual general meeting, A1C, Table, Investment, DXCM, Video game, Security (finance), Bank

GAAP operating income of $205.5 million or 21.1% of revenue, an increase of 190 basis points compared to the third quarter of 2022.

Key Points: 
  • GAAP operating income of $205.5 million or 21.1% of revenue, an increase of 190 basis points compared to the third quarter of 2022.
  • 1 Third quarter of 2023 organic revenue is $969.1 million and excludes $5.9 million of foreign exchange impact.
  • Revenue: In the third quarter of 2023, worldwide revenue grew 27% to $975.0 million on a reported basis, up from $769.6 million in the third quarter of 2022.
  • Accordingly, a reconciliation of total Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin is not available without unreasonable effort.